# Jiangsu Quan Xin Biomedical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiangsu-quan-xin-biomedical-co

- Industry: Biotechnology
- Headquarters: Taizhou, China
- Website: www.qyuns.net
- Latest round: Series C (Mar 7, 2022)
- Investors on record: 11

## About

Based in Taizhou, China and founded in 2015, Jiangsu Quan Xin Biomedical Co., Ltd. operates as an antibody drug developer, focusing on the treatment of autoimmune diseases. It established clinical development center in Beijing and Shanghai. The company has over 80 domestic and foreign patents. The founder and chairman of the company, Jiwan Qiu graduated from Zhejiang University and has working experience in biotechnology and pharmaceutical industry. The COO of the company, Jianwei Li graduated from University of Bern and has worked in SymyxTechnologiesInc. and Allergan,Inc. In March 2024, the company raised USD 25 million in pre-IPO funding. In March 2024, Qyuns Therapeutics Co., Ltd. was listed on the Hong Kong Stock Exchange.

The company focuses on the research and development of biopharmaceuticals for autoimmune and allergic diseases. There are 9 product pipelines under research, including 1 drug that has been accepted by BLA. The medicines produced by the company include monoclonal analogues and innovative monoclonal antibodies. The products include QX002N, QX004N, QX005N, and QX008N. QX004N is suitable for psoriasis and Crohn's disease. The medicines can be used in curing immune disorders such as skin, rheumatism, respiratory and digestive diseases.

In 2022, the company's net income was CNY -312.38 million.

The company used the proceeds from the listing for clinical trials.

## Funding rounds

- Series C, Mar 7, 2022 — Triwise Capital, Kinsight Capital, Shenzhen Kaitian Fund Management
- Series B, May 6, 2020 — Shenzhen Lucky Source Investment Management, Shenzhen Jiayin Fund Management
- Series B, Jun 19, 2019 — Hongtai Aplus, Triwise Capital, Tongren Boda Capital
- Series A, Jun 3, 2016 — Huaxin Venture Capital, Tongren Boda Capital, Taizhou Rongjianda Venture
- Angel, Nov 24, 2015 — Efung Capital, Nanjing Huayuxiang Asset Management Center (General Partnership)

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Angel
- Nanjing Huayuxiang Asset Management Center (General Partnership) — Angel
- Huaxin Venture Capital (https://capitalatlas.ai/funds/huaxin-venture-capital) — Series A
- Tongren Boda Capital (https://capitalatlas.ai/funds/tongren-boda-capital) — Series A, Series B
- Taizhou Rongjianda Venture — Series A
- Hongtai Aplus (https://capitalatlas.ai/funds/hongtai-aplus) — Series B
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series B, Series C
- Shenzhen Lucky Source Investment Management (https://capitalatlas.ai/funds/shenzhen-lucky-source-investment-management) — Series B
- Shenzhen Jiayin Fund Management — Series B
- Kinsight Capital (https://capitalatlas.ai/funds/kinsight-capital) — Series C
- Shenzhen Kaitian Fund Management — Series C